Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Having a weak and an uninspiring CEO like Keith Katlin who is
always "excited" about the future of Avanir has done little to inspire
confidence in the face of these troubling and potentialy catastrophic
events. $2.80 really.... Where is the leadership when your company
And stock is under siege, Notice how swiftly Mizhuto downgraded the
stock..... Everyone it seems is disgusted with Avanir's management team
Dont you think Merck would have uncovered the alleged off label usage by the sales team
before they forged a relationship with Avanir.
This was a well orchestrated "drive by" short attack , a beautifully timed and executed
plan that frightened many weak hands in surrendering their shares to short covering.......
This is beautiful... its been a very long and painful ride holding this stock from
the Yakka Yak days through the Boy Blunder fiasco to KK and his beautiful execution
of Nuedexta that many shorts tried in vain to derailed.......
Just beautiful.....
A down draft, are you kidding me, that has been absolute unmitigated disaster
since FDA approval, and if you have been paying attention, Katlin's stock
sales always seem to avoid these plunges, he sells just before the stock tanks.
Its safe to say that Keith Katlin is a glorified accountant who
should be relieved of his duties. And no wonder Siebold jumped ship early on,
this has been an abysmal failure.
The Michael J. Fox Foundation Awards Grant To Support Avanir Pharmaceuticals
ALISO VIEJO, Calif., Oct. 23, 2012 /PRNewswire via COMTEX/ -- Avanir Pharmaceuticals, Inc. AVNR +0.63% today announced that The Michael J. Fox Foundation has awarded the company a grant to evaluate the safety and efficacy of AVP-923 (dextromethorphan hydrobromide and quinidine sulfate) for the treatment of levodopa-induced-dyskinesia (LID) in Parkinson's disease (PD).
"The development of effective drugs that can reliably suppress L-dopa-induced dyskinesia is a very high priority in Parkinson's research," said Anthony E. Lang, MD, Professor and Director of the Division of Neurology and Chair for Parkinson's Disease Research at the University of Toronto. "I am excited at the prospects of the work being done by The Michael J. Fox Foundation and Avanir directed at this important unmet need in the Parkinson's community."
"We are proud to be recognized by The Michael J. Fox Foundation with this award," said Joao Siffert MD, senior vice president of research and development at Avanir and principal investigator of the study. "Their support will enable this important study in LID and further validates the rationale for testing AVP-923 for diverse central nervous system disorders of high unmet medical need."
About the StudyThis proof-of-concept, double blind, randomized, crossover study will compare AVP-923 (45 mg of dextromethorphan / 10 mg of quinidine) with placebo for treatment of LID. The study will enroll PD patients across three study centers in the US and Canada. Study participants will receive, in a random order, a 2-week treatment with AVP-923 and a 2-week placebo treatment, separated by a 2-week break. At the end of each 2-week treatment period, patients will receive a 2-hour levodopa infusion to test the drug effect on dyskinesia. Patients will be carefully monitored throughout the 6-week study for side effects, Parkinson's symptoms and general health status. The results of this study will help inform future development of AVP-923 for LID.
wonder if Katlin will break out a new and improved short dance at
the upcoming CC after his first one proved to be disastrous for
shareholders. Or better yet instead of taunting shorts and playing
the fool maybe he can justify the obscene pay, bonus' and perks that
he and his crew have been enjoying while overseeing an abysmal
stock performance.
Jefferies just cut AVNR pt. from $3.50 to $3.00.
Notice the quick recovery from this morning's plunge, looks to me like short covering
before market close.......
I share your frustration BUT those insider sales are planned and automatic stock sales in
amounts and dates set fourth under the 10b-5 plan. The reason for it is because insiders often can't sell because they have insider information. Trading with inside information is illegal, ask
Raj from Galleon and Martha Stewart.But by having an automatic plan, the insider is not trading on inside information (the trade is automatic and will happen regardless of any inside knowledge).
what's today excuse..... Looks like it will be under 2 bucks at this rate,
another bonus for management for wiping out shareholders.
give me a break, this stock has performed dreadfully when the market is up and/or
down. Management has been tone deaf when it come to shareholders but very active
in selling shares and awarding themselves big bonus'.
Keith Katkin and his greedy team have been a disaster, and I think Siebold saw
what the future looked like and fled.
That is a garbage website, any loser can post spam to it...... sheesh....
Its from '09 but still relevant on the criminality of Creamer....
and his boss: the gesticulating con man Creamer:
http://www.marketrap.com/article/view_ar...
The paid hack: Adam Feuerstein exposed !!
http://www.exposeadam.com/
"there is no factual or logical case for the short argument"
I agree BUT the market isn't guided by reason,
FEAR is the prime motivator, a tool used
with skill by shorts in hammering away at Avanir.
actually we may get a heads up on monday in spite of
the holiday, and as for being a hedgie tool:nope,
just concerned like all legitimate longs should be
on the many hits this fledgling bio is taking
since approval.
I'm not as confident in the future of this company
as I once was, these coordinated hits by shorts to take
down the stock have been flawless. From the weak launch
that surprised analysts,to the congressional inquiry,and
now the ANDA filing are having the desired effect in
making the short position stronger.
We all know Nuedexta works, there is a market but
the green horn: Keith K. has performed abysmally
since approval. What is the guy doing to counter
these unrelenting attacks that have cost shareholders
dearly.
also,if the script data on Monday is weak, we'll see
the $2's.
actually its a clever tactic by shorts to trigger stop losses allowing them to cover.
Today FEAR rules, forget price discovery........
That is the way I'm reading it, the silver lining to today's stock plunge.
Also, don't forget Martin S. has a very large short to cover for his masters.
please stop with the platitudes, the reason for the
plunge: a generic has been "filed"with the FDA....
Can't verify it yet but it appears on the FDA website
"filed" on the 7th of June.
Those PT's will inevitably go higher as market adoption increases...
also, we need an investment firm that doesn't have a banking relationship
with Avanir to begin coverage and rate it a buy.
maybe so but that "noise" did have a deleterious effect on the stock price.
Also, I think Marty is a bagman for a powerful hedge fund who's reach
extends all the way into the halls of congress. He is no lone wolf
operating for himself, he's not that smart.
Besides the toothless and emasculated SEC faces a herculean task in "monitoring" these out-of-control hedge funds. I just wouldn't put much faith in this new rule because some of the funds
are run by very smart but unsavory characters.
I think its more window dressing to show the retail investor that the SEC is doing something
about the flagrant criminality that has consumed Wall Street.
http://www.sec.gov/rules/proposed/ia-2266.htm
""While hedge funds are not required to register themselves, reputable hedge funds usually are." "
Not if the SEC commissioners vote today to pass a long-awaited rule that would
require hedge-fund and private equity managers with more than 100 million
in assets to register with the agency.
Marty's "operation" doesn't qualified thus he is pretty much saying he isn't reputable.
From a poster on YMB about Martin the short:
https://sites.google.com/site/vatsire/Searching-for-Martin-Shkreli
AF tweeted yesterday:
"down today likely b/c Nuedexta weekly Rx down 2 straight weeks."
Hoping the NRx and TRx are made public, also waiting for the 13F
which will show tutes ownership.
Someone "reporting" that scripts took a nosedive last week, if true than that's the reason for the severe drop today and shorts celebrating. Also, maybe that analyst from Jefferies had a head ups
on the numbers an lower his PT on the stock.
absolute BS.... CEO CANNOT reject nor accept buyout w/o shareholder approval
shareholders should pay attention to the growing short position and Canaccord
meek buy rating tempered with a warning about early sales aren't predictive
of future earnings of Nuedexta.
I think shorts will prevail in May due to the lousy script data and drive the pps.
to new lows....
Your quoting from a nobody..... we need new investment analysts who have no financial
relationship to Avanir to weight in unlike the current crop of analysts covering
Really.... did you check the price today, this is absolutely ugly, no support
until those elusive revs. appear until then this is going lower.
" 3.38 200 mda --not going back there."
unfortunately you may be eating those words.......
stock has no support, shorts have complete control with the help of Katlin's
new dilution, I'm concerned about those margin calls being triggered as
the price falls, we could quickly fall back near 3.00.
We are at the mercy of shorts, they control the stock until the next positive event ie
good sales numbers, then covering will occur and we move up.
Its been a very tough ride up to the approval back in Oct. 10 and now until those
sales start trickling in and The Street has an idea on a fair market cap.
At the moment I'm not happy with the performance of Katlin and his
unbounded greed at the expense of shareholders, he's been an absolute pig
and untrustworthy, his 25 million in sales projection at the recent cc i take
with a grain of salt.